Novo Nordisk Foundation
Overview
Novo Nordisk Foundation is an independent Danish enterprise foundation with philanthropic objectives to improve people's health and the sustainability of society and the planet. It funds its grants and initiatives through the financial returns generated by its wholly-owned holding and investment company, Novo Holdings A/S, which holds the controlling interest in Novo Nordisk A/S and Novonesis A/S.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Macro Biologics | Dec 2025 | Grant | Co-investor |
| QuNorth | Aug 2025 | Grant | Lead |
| SelekTx | Dec 2024 | Grant | Co-investor |
| SymbioMatch | Dec 2023 | Grant | Co-investor |
| TROYA Therapeutics | Dec 2023 | Grant | Co-investor |
Key People
Aslak Lau Rolvsen
Learning & Development Partner
Bettina Louise Lynghede
P&O Development Partner, People & Organization, P&O Partner, People & Organization
Helle Helgren
Internal Change and Comunication Partner, P&O Development
Joan Bentzen
Impact partner
Sidsel Ebbesen
P&O Partner
Charlotte Bailey
Senior Portfolio Manager
Jesper Laursen
Senior Communication Partner
Rikke Christensen
Senior Impact Partner at Novo Nordisk Foundation, Senior Impact Partner
Susanne Toft
Senior P&O Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
